Latest research

Results of the analysis of the 6 year data of the Department of Health (DH) MS Risk-sharing Scheme (RSS), published in the Lancet Neurology today, show that the disease modifying drugs Avonex, Betaferon, Copaxone and Rebif are cost effective and are clinically effective in...

Researchers have started to recruit 440 people with secondary progressive MS across the UK for a trial that will look at drugs that may limit the progression of MS.

This study aimed to find out more about how bladder problems interfere with quality of life for people with MS and to better understand what could be done to help.

We’ve all heard stories about miracle cures for MS; these days they often involve stem cells. Neil Scolding is the Burden Professor and Director of the Bristol Institute of Clinical Neurosciences, and he has a special interest in MS and cell therapy.

A review of studies into swallowing problems in multiple sclerosis finds they are common but estimates vary.

About half of all people with MS have problems at some time with aspects of thinking such as memory, concentration or problem solving.